Cytek BioSciences, Inc. (CTKB) News
Filter CTKB News Items
CTKB News Results
|Loading, please wait...|
CTKB News Highlights
- CTKB's 30 day story count now stands at 2.
- Over the past 16 days, the trend for CTKB's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
Latest CTKB News From Around the Web
Below are the latest news stories about Cytek Biosciences Inc that investors may wish to consider to help them evaluate CTKB as an investment opportunity.
While some investors are already well versed in financial metrics (hat tip), this article is for those who would like...
Operations to Accommodate Increasing Demand for Cell Analysis SolutionsFREMONT, Calif., Jan. 05, 2022 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (Nasdaq: CTKB), a leading cell analysis solutions company, today announced that it has opened a new facility in Fremont, California – tripling its current manufacturing capacity in order to meet growing global demand for cell analysis solutions. In addition to the new Fremont location, Cytek has also opened new offices in Seattle, Washington, which are
New York, NY, based Investment company Orbimed Advisors Llc (Current Portfolio) buys Adagio Therapeutics Inc, Zimmer Biomet Holdings Inc, Biogen Inc, HCA Healthcare Inc, Erasca Inc, sells Prelude Therapeutics Inc, Aurinia Pharmaceuticals Inc, Ascendis Pharma A/S, Natera Inc, Anthem Inc during the 3-months ended 2021Q3, according to the most recent filings of the investment company, Orbimed Advisors Llc.
Cytek BioSciences (NASDAQ:CTKB) was downgraded by Zacks Investment Research from a buy rating to a hold rating in a report released on Tuesday, Zacks.com reports. According to Zacks, Cytek Biosciences Inc provides cell analysis solutions. The company developed high-resolution, high-content and high-sensitivity cell analysis technology called Full Spectrum Profiling. Cytek Biosciences Inc is based in 
Zacks Investment Research upgraded shares of Cytek BioSciences (NASDAQ:CTKB) from a hold rating to a buy rating in a research note issued to investors on Thursday, Zacks.com reports. Zacks Investment Research currently has $21.00 target price on the stock. According to Zacks, Cytek Biosciences Inc provides cell analysis solutions. The company developed high-resolution, high-content and 
During the last session, Cytek Biosciences Inc. (NASDAQ:CTKB)s traded shares were 0.9 million. At the end of the trading day, the stocks price was $17.65, reflecting an intraday gain of 1.44% or $0.25. The 52-week high for the CTKB share is $28.70, that puts it down -62.61 from that peak though still a striking 3.06% Now Is A Good Time To Buy Cytek Biosciences Inc. (NASDAQ: CTKB) Read More »
Cytek BioSciences, Inc. (NASDAQ:CTKB)s share price rose 4.7% during trading on Wednesday . The stock traded as high as $18.43 and last traded at $18.43. Approximately 265 shares traded hands during mid-day trading, a decline of 100% from the average daily volume of 258,158 shares. The stock had previously closed at $17.61. CTKB has been 
Cytek BioSciences (NASDAQ:CTKB) was upgraded by Zacks Investment Research from a hold rating to a buy rating in a research report issued to clients and investors on Friday, Zacks.com reports. The firm presently has a $22.00 price objective on the stock. Zacks Investment Researchs target price would suggest a potential upside of 17.90% from the 
Quanterix (NASDAQ:QTRX) and Cytek BioSciences (NASDAQ:CTKB) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, valuation, profitability, earnings, analyst recommendations, institutional ownership and dividends. Institutional and Insider Ownership 82.1% of Quanterix shares are held by institutional investors. Comparatively, 7.3% of Cytek 
Cytek BioSciences (NASDAQ:CTKB) and Quanterix (NASDAQ:QTRX) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, analyst recommendations, risk, profitability, earnings, institutional ownership and dividends. Analyst Recommendations This is a summary of current ratings and price targets for Cytek BioSciences and Quanterix,